Receive report status and quick access to patient information /// EXPLORE NOW Tempus One: New AI Clinical Assistant Available for All Providers
ORDER A TEST Log In Contact Us
Hero Background

LIFE SCIENCES

Discover, design, and deliver the right drug for the right patient

Tempus provides integrated solutions to help meet your needs from early discovery through commercialization.

CONTACT US

Our Solutions

  1. Sequencing

    Use our genomic platform to prospectively sequence through clinical trials and retrospectively support research priorities.
  2. Data Collaborations

    Leverage real-world datasets of matched molecular and clinical data with digital whole slide pathology images to uncover new insights across the research and development spectrum.
  3. Biological Modeling

    Leverage our robust biobank of patient-derived tumor organoids to accelerate drug discovery.

  4. Companion Diagnostics

    Integrate CDx claims into Tempus assays through a validated and established sequencing platform to pursue companion diagnostic biomarkers.
  5. Multi-omics

    Discover unique molecular targets, track methylation patterns, and build multimodal datasets with our robust suite of high throughput multi-omic solutions.

  6. Clinical Research Organization Services

    Bring discoveries from the lab to market through our full-service CRO.
  7. Clinical Trial Enrollment

    Utilize NGS and EMR integrations to identify patients that match your study's eligibility criteria, including targetable biomarkers from DNA and RNA.
  8. Tempus Studies

    Leverage our end to end solutions to design and execute Tempus-sponsored clinical trials for therapeutics, devices, and diagnostics from study concept to registrational filing.

We partner with scientists and researchers to accelerate the drug development process

  • 90%

    of the top 20 pharma oncology companies partner with Tempus

  • 200+

    biopharma partnerships

image description

AstraZeneca

Enhance data-driven R&D strategy

Read press release

GSK

Leveraging diagnostics and data to drive next-generation drug development

Watch webinar

Kronos

Advance current clinical candidate markers

Read press release

Eli Lilly

Increasing accessibility to testing

Read press release

GSK

Intersection of genomics and machine learning

Read press release

AstraZeneca

Increasing Probability of Technical Success (PTS)

Read blog

Janssen

Using RWD

Read article

AstraZeneca and Pfizer

Data-driven CDx development

Read article

TScan

RWD and immuno-oncology

Read article

GSK

Using data and AI/ML to achieve precision medicine

Read article

AstraZeneca

Multimodal data for Probability of Technical Success (PTS)

Watch webinar

Eisai

The evolution of RWE and HEOR

Read article

Sermonix

Trial enrollment acceleration

Read case study

Gilead

RWD and decision making

Read article

TScan

Partner to develop assays

Read press release

AstraZeneca

Clinical trials for novel therapies

Read press release

Actuate Therapeutics

Use liquid biopsy and RUO DNA Methylation to discover and validate

Read press release

Genmab

Discover new targets

Read press release

Janssen

Leveraging AI/ML for RWD

Read press release

AstraZeneca

Strategic collaboration

Read press release

Bristol Myers Squibb

Discover RNA based targets

Read press release

Gilead

Biomarker innovation

Watch webinar

Kronos Bio

RWE for drug development

Read article

Sermonix

Patient recruitment

Read article

Geisinger

AI and ECG

Read blog

Genmab

Multimodal RWD

Read article

Aadi Bioscience

Accelerate trial enrollment

Read case study

A2 Bio

NGS to power R&D

Read article

Kronos Bio

Collaboration around data and organoids

Read press release

Kartos Therapeutics

Progressing the goal of innovative therapies

Read press release

Data Collaborations

  • 6M+

    de-identified research records to power scientific discovery to improve patient outcomes

  • 700K+

    records with matched clinical data linked with genomic information to understand driver mutations and outcomes associations

  • 150K+

    records with full transcriptomic data for interrogating tumor biology and mechanisms of action

image description

Sequencing

  • 6

    NGS tests to support clinical trial and research sequencing

  • 6K+

    oncologists rely on Tempus as their precision medicine partner

image description

Clinical Trial Solutions

  • 10

    days on average to activate a new site

  • 200+

    provider networks and research institutions in the TIME Trial® Program

  • 24K+

    patients have been identified for potential enrollment into clinical trials in our network

image description
Our Impact

Thanks to Tempus, we are able to identify patients that can be helped with our proprietary TMod™ platform. Without them, we wouldn’t be able to do this.

William Go, SVP, Head of Development at A2 Biotherapeutics (TMod™ is a trademark of A2 Biotherapeutics)

Our Impact

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Learn more about our partnership with Genmab
Our Impact

Bayer’s strong focus in precision medicine combined with Tempus’ unique testing offering has culminated in this collaboration to bring genomic testing to cancer patients.

Bhavesh Ashar, Senior Vice President, Head of U.S. Oncology at Bayer

Learn more about our partnership with Bayer
Our Impact

Our partnership with Tempus will enable us to collect important retrospective information about the patients enrolled in the dose escalation part of our clinical trial that we can potentially use to inform enrollment in the expansion stage of our study.

Jorge DiMartino, Chief Medical Officer and Executive Vice President, Clinical Development at Kronos Bio

Learn more about our partnership with Kronos

Featured Resources

View all RESOURCES
  • UPCOMING WEBINAR:

    The value of RNA sequencing in drug discovery

    Learn the value of RNA Sequencing in identifying genetic variants overexpressed in tumors that are measurable by RNA-Seq but not DNA-Seq.

    Read more
  • UPCOMING WEBINAR:

    Accelerating patient enrollment with just-in-time trials: TriHealth on the TIME program

    The traditional model of activating clinical trials is widely acknowledged as inefficient. The process of establishing a clinical site, negotiating partnerships between sites and sponsors, then attempting to recruit eligible patients in nearby areas can take many months, and it becomes a burden to trial site staff, sponsors, and patients.

    Read more
  • UPCOMING WEBINAR:

    Q&A: The evolution of RWE & HEOR—A conversation with two biopharmaceutical executives

    Dr. Gupta and Dr. Iyer discuss the evolution of RWD in HEOR with Dr. Sasser.

    Read more
  • UPCOMING WEBINAR:

    Q&A: Using liquid biopsies to build CDx in pancreatic cancer with Actuate Therapeutics

    Dr. Andrew Mazar of Actuate Therapeutics shares his perspective on liquid biopsy as a tool for CDx and drug development in pancreatic cancer.

    Read more
  • UPCOMING WEBINAR:

    AACR GSK Product Theater

    The Tempus Spotlight Theater this year was on “Delivering on the Promise of Precision Medicine: Leveraging Diagnostics and Data to Drive Next-Generation Drug Development” and was a fireside chat between Kate Sasser, Chief Scientific Officer at Tempus and Anne-Marie Martin, SVP Global Head in the Experimental Medicine Unit at GSK.

    View more
  • UPCOMING WEBINAR:

    The next evolution in drug development

    Hear from Janssen’s Dr. Najat Khan to find out how the company is applying advanced AI algorithms to RWD—with groundbreaking results.

    Read more
  • UPCOMING WEBINAR:

    New ways to optimize R&D partnerships

    Learn how Tempus and Kronos are partnering to leverage RWD’s potential to drive innovations in drug discovery and clinical development.

    Read more
  • UPCOMING WEBINAR:

    Enhanced biomarker discovery and design

    Combining sequencing, analytics, and data licensing with Tempus allows you to uncover new insights across R&D. Learn how one company made it happen.

    Read more
  • UPCOMING WEBINAR:

    Powering discovery: Tempus multimodal database

    Read about an example of how Tempus Multimodal Data enabled a pharmaceutical company to more quickly identify pancreatic cancer subtypes’ molecular signatures.

    Read more

Tempus empowers you to make smarter, faster, and more efficient decisions

Get customized solutions for your needs.